Recording Date: January 30th, 2020
Presenter: Don Rule, CEO of Translational Software
Summary of Webinar
Don Rule, TSI CEO, spoke about the confluence of issues impacting the pharmacogenetic space in 2019. Included as talking points around the headwinds impacting the market: Implementation of EKRA in Q4 2018, CMS local coverage decisions regarding pharmacogenetic reimbursements, FDA activities in pursuit of regulating the pharmacogenetic space. The other half of the presentation was about the positive opportunities that lie ahead for the space beyond the aforementioned issues. The future of PGx is indeed bright.
About the Presenter
Don Rule is the founder and CEO of Translational Software. After working decades in the technology vertical for companies like D&B and Microsoft, he was exposed to bioinformatics and saw a vision for how pharmacogenetics could be a leading edge solution within precision medicine and founded the company in 2009. His desire is to assist in democratizing pharmacogenetics and precision medicine broadly.